Industry News
Tumour busting drug on trial
An anti-tumour durg, AQ4N, which destroys tumour cells that other anti-cancer treatments cannot - is undergoing clinical trials at Leicester Royal Infirmary and Oxford's Churchill Hospital in the UK.
[ + ]How nerve cells form connections
Scientists at the University of California, San Diego have produced images of brain cells forming temporary and permanent connections in response to various stimuli.
[ + ]The performance of Australian science
Is Australia's scientific performance being watered down due to the pressures brought about by policy changes over a decade ago, or is it simply the case that university researchers are becoming much more clever in how they publish?
[ + ]Antibiotics to beat superbugs
Antibiotics to combat hospital superbugs as well as tuberculosis and salmonellas are being developed by Dr Jim Naismith of St Andrews University, Scotland.
[ + ]More tailoring required in biotech strategy
The Australian Biotechnology Association has called for a more co-ordinated, strategic approach to the development of the biotechnology industry.
[ + ]Protein with dual role in regulation of cellular processes
The unique dual-action role of a natural regulatory protein that controls cellular function has been described by researchers at the University of California, San Diego (UCSD) School of Medicine.
[ + ]Qld establishes centre of excellence
The Queensland government and The University of Queensland have announced a $50 million Australian Institute of Bio-Engineering and Nanotechnology would be established in Brisbane.
[ + ]Leukaemia vaccine breakthrough
An effective leukaemia vaccine could be available within a few years following a breakthrough by scientists in the UK.
[ + ]A different CRC needed for commercialising research
A study into Australian entrepreneurship has recommended the creation of a Cooperative Development Centre (CDC) Program, modelled on the successful Cooperative Research Centre (CRC) Program, and which would aim at developing expertise in commercialising research output.
[ + ]UTS nanotech work to expand
Dr Grant Griffiths, recently appointed acting director of the Institute for Nanoscale Technology, plans to strengthen the focus of UTS research and scholarship in nanotechnology.
[ + ]Researchers distinguish another type of leukemia
Researchers who have studied the activity of thousands of genes in a drug-resistant form of childhood leukemia are now proposing that the disease be called mixed-lineage leukemia (MLL) because it is a distinct disease, and not a subtype of the more prevalent acute lymphoblastic leukemia (ALL).
[ + ]Sweet news for diabetics
UTS scientists have made significant progress towards their goal of an effective gene-therapy treatment for diabetes that would make insulin injections obsolete.
[ + ]NHMRC invests $366 million
Nationally, the NHMRC is funding 408 project grants ($143 million), 16 new program grants ($115 million), and 46 fellowship grants ($25.5 million), totalling $283.5 million.
[ + ]Simplified method for detecting antibodies
A Ben-Gurion University research team, headed by Dr. Raz Jelinek, has recently designed one of the simplest, most rapid approaches to detect specific antibodies.
[ + ]Lab training boosts foot and mouth preparedness
Australia's diagnostic capability to deal with any potential large-scale outbreak of foot and mouth disease is being increased, thanks to two training workshops.
[ + ]